Steroid Refractory Acute Graft Versus Host Disease (SR aGVHD)

DBCOND0162211Immune System Diseases Wounds and Injuries

Steroid Refractory Acute Graft Versus Host Disease (SR aGVHD) is the indication for 2 drugs in DrugBank. It is covered by 2 curated, structured indications.

Also known as: Steroid Refractory Acute Graft Versus Host Disease · Steroid-refractory Acute Graft-versus-Host Disease · Steroid-Refractory Acute Graft Versus Host Disease · Steroid-refractory Acute Graft-versus-host Disease(SR-aGVHD)
Classified under: Immune System Diseases
Wounds and Injuries
Indicated drugs: Alemtuzumab
Remestemcel-L

What you can answer from here — as of October 25, 2026

2Indicated drugsWith each drug's targets and mechanism

Listed above

2Structured indicationsPopulation, line of therapy, route and combination as fields, not prose

12Clinical trialsPhase, status and sponsor resolved per trial

Which approved drugs for Steroid Refractory Acute Graft Versus Host Disease (SR aGVHD) share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account